J
Jan Budczies
Researcher at University Hospital Heidelberg
Publications - 185
Citations - 16222
Jan Budczies is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 48, co-authored 166 publications receiving 12762 citations. Previous affiliations of Jan Budczies include German Cancer Research Center & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
Subgroup-specific immune and stromal microenvironment in medulloblastoma.
Michael Bockmayr,Malte Mohme,Frederick Klauschen,Beate Winkler,Jan Budczies,Stefan Rutkowski,Ulrich Schüller +6 more
TL;DR: A mild, but subgroup-specific infiltration of immune cells in medulloblastoma is suggested, indicating distinct types of local tumor immunosuppression.
Journal ArticleDOI
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Daniel Kazdal,Volker Endris,Michael Allgäuer,Mark Kriegsmann,Jonas Leichsenring,Anna-Lena Volckmar,Alexander Harms,Martina Kirchner,Katharina Kriegsmann,Olaf Neumann,Regine Brandt,Suranand Babu Talla,Eugen Rempel,Carolin Ploeger,Moritz von Winterfeld,Petros Christopoulos,Diana M. Merino,Mark Stewart,Jeff Allen,Helge Bischoff,Michael Meister,Thomas Muley,Felix J.F. Herth,Roland Penzel,Arne Warth,Hauke Winter,Stefan Fröhling,Solange Peters,Charles Swanton,Michael Thomas,Peter Schirmacher,Jan Budczies,Albrecht Stenzinger +32 more
TL;DR: The data demonstrate that, in addition to technical aspects like germline filtering, the tumor content and spatially divergent mutational profiles within a tumor are relevant factors influencing TMB estimation, revealing limitations of single sample based TMB estimations in a clinical context.
Journal ArticleDOI
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
Ruza Arsenic,Denise Treue,Annika Lehmann,Michael Hummel,Manfred Dietel,Carsten Denkert,Jan Budczies +6 more
TL;DR: NGS is recommended as follows for correctly assessing the mutation status of PIK3CA in breast cancer, especially for cases with low tumor content, for the detection of subclonal mutations, and for simultaneous mutation detection in multiple exons.
Journal ArticleDOI
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Mark Kriegsmann,Volker Endris,Thomas Wolf,Nicole Pfarr,Albrecht Stenzinger,Sibylle Loibl,Carsten Denkert,Andreas Schneeweiss,Jan Budczies,Peter Sinn,Wilko Weichert +10 more
TL;DR: A breast cancer specific gene panel for semiconductor-based sequencing comprising 137 amplicons covering mutational hotspots in 44 genes is designed and validated and could demonstrate that breast cancer targeted hotspot sequencing is feasible in a routine setting and yields reliable and clinically meaningful results.
Journal ArticleDOI
Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma.
Petros Christopoulos,Martina Kirchner,Farastuk Bozorgmehr,Volker Endris,M. Elsayed,Jan Budczies,J. Ristau,Roland Penzel,Fjf Herth,C.P. Heussel,Martin E. Eichhorn,Thomas Muley,Michael Meister,J.R. Fischer,Stefan Rieken,Felix Lasitschka,Helge Bischoff,Rocio Sotillo,Peter Schirmacher,Michael Thomas,A. Stenzinger +20 more
TL;DR: TP53 mutations and V3 are independently associated with enhanced metastatic spread, shorter TKI responses and inferior overall survival in ALK+ lung adenocarcinoma and define a patient subset with very poor outcome.